Oktober 11, 2026

retatrutide

Eli Lilly Stock 2026: Foundayo, Retatrutide, Zepbound & Valuation

Eli Lilly’s Q2 revenue jumped 48% to $23 billion as Mounjaro and Zepbound dominated growth. I examine obesity economics, pipeline depth, pricing, manufacturing and LLY valuation.

Mehr lesen